The 2025 FDA Enforcement Surge: What 200+ Warning Letters Mean for Telehealth and Clinic Marketing

How much did FDA enforcement of drug advertising change in 2025? The agency issued more than 200 enforcement letters challenging drug advertising and promotion, the highest annual total in nearly 25 years [1]. Most of that volume came after September 9, 2025, when HHS and FDA jointly announced an aggressive enforcement campaign against direct-to-consumer drug ads [2]. Of the 74 letters sent to drug manufacturers, only 5 predate that announcement [1]. The other 126-plus letters went to online retailers, telehealth providers, and compounding pharmacies marketing compounded drugs to consumers [1].

TL;DR

• The volume is real and recent. FDA issued more than 200 enforcement letters in 2025 on advertising and promotion, a 25-year high [1]. The agency described its new posture as “no longer tolerate” misleading drug ads and said it would “aggressively deploy its available enforcement tools” [3].
• September 9, 2025 was the inflection. HHS and FDA launched the crackdown jointly, following a Presidential Memorandum the same day directing transparency and accuracy in direct-to-consumer prescription drug advertising [2].
• Telehealth, social media, and online retailers are explicitly in scope. More than 40 of the September warning letters went to compounding pharmacies and telehealth companies, including eDrugstore and Hims & Hers, and the FDA specifically named paid social media influencer posts on TikTok and Instagram as enforcement surfaces [4].
• Compounded GLP-1 and erectile-dysfunction drugs drew the largest single cluster. 58 of the Warning Letters issued on September 9 targeted compounded GLP-1 agonists and ED drugs by name [1].
• The exposure is your copy, not your intent. Most flagged language is copied from a supplier, inherited from old pages, or written by a freelancer reaching for a stronger verb. The phrasing is what gets cited.

The number, and why it is structurally different from prior years

Two hundred-plus letters in twelve months is not a marginal step. King & Spalding’s 2025 Year in Review puts the total at the highest annual count in nearly a quarter century [1]. For context, the FDA’s Office of Prescription Drug Promotion issued zero Warning Letters in 2024 [5]. The 2025 total is a regime change, not a fluctuation.

The composition of the 2025 letters shows who the agency thinks is shaping consumer drug advertising. The recipient-side breakdown of the public record:

Recipient category	2025 letters	Notes
Drug manufacturers	74	10 Warning Letters + 64 Untitled Letters [1]
Online retailers, telehealth, compounding pharmacies	126+	Promotion of unapproved drugs to consumers [1]
Medical-device companies	32	Separate Warning Letter track for device marketing [1]
Total disclosed	200+	Highest annual count in ~25 years [1]

Of the 74 manufacturer letters, only 5 were issued before September 9, 2025 [1]. Sixty-nine of seventy-four manufacturer actions, and most of the consumer-channel actions, came in the four months after the joint HHS-FDA announcement. The agency posted an additional 11 Untitled Letters from the September 9 cohort later that month, bringing prescription-drug compliance correspondence to 60 by the end of September [5]. That cadence is the new baseline.

What the September 9 announcement actually changed

On September 9, 2025, HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Marty Makary released a joint announcement, “FDA Launches Crackdown on Deceptive Drug Advertising,” following a Presidential Memorandum the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements” [2]. Three operational shifts followed:

1. Volume. FDA sent thousands of letters to manufacturers ordering removal of non-compliant promotional materials and issued approximately 100 cease-and-desist letters in addition to the formal Warning and Untitled Letters [2].
2. Loophole closure. FDA opened rulemaking aimed at the 1997 “adequate provision” regulation that has let broadcast and digital ads omit detailed risk information by referring viewers elsewhere [2].
3. Surveillance. The agency reported deploying AI and other tools to proactively surveil and review drug ads, including online and social media promotion [2].

The accompanying enforcement, more than 40 September warning letters to compounding pharmacies and telehealth companies, made clear that “drug advertising” in the new posture includes telehealth marketing pages, online retail product pages, and paid social media content [4].

The pattern in the letters: what claims, what surfaces, what verticals

The letters cluster around a small set of marketing patterns that recur across recipients. From the public record and from the FDA / FTC Atlas corpus of tracked actions, the dominant patterns are these:

Pattern	What it looks like	Why it triggers
Compounded drug presented as the approved brand	A product page names semaglutide or tirzepatide with no compounding disclosure, framed as the branded product	Compounded drugs are not reviewed by FDA the way branded products are; copy that conflates them implies a status the product does not carry [7]
Brand-equivalence claim	Equivalence language placing a compounded preparation next to a named brand drug like Ozempic or Mounjaro	Equivalence implies bioequivalence data the clinic does not hold; FTC treats it as an unsubstantiated comparison [8]
Off-label or unapproved-use promotion	Marketing an unapproved use as a routine clinic offering	Promotes an unapproved drug under FD&C Act §201(g) [9]
Paid endorsement or influencer post without risk disclosure	A TikTok or Instagram creator naming a drug without balanced safety information	FDA specifically named paid social media influencer posts as a 2025 enforcement target [4]
Absolute-safety language	Language asserting a treatment is risk-free or carries no adverse events	Presumptively deceptive; FTC standard requires accurate safety description [8]
Outcome-promise language	Money-back-framed clinical promises or assured-result phrasing	Clinical outcomes vary by patient; treated as a deceptive act under Section 5 [8]

The vertical concentration is consistent with what is already in the Atlas. Compounded GLP-1 agonists, erectile-dysfunction drugs, peptides, stem cell and regenerative offerings, and medical-spa injectables account for most of the consumer-channel letters [1][7]. The pattern detail by vertical lives in the marketing claims that trigger FDA Warning Letters, where weight-loss clinics cross the FDA’s line on compounded GLP-1, and the vertical Atlas categories.

What this means if you run an independent clinic or telehealth service

The agencies have done you a favor in one respect, which is that the new posture is concrete. Every September letter is a published document quoting the recipient’s own marketing back to them. That gives you a usable map of what to remove or rewrite on your own site, your ad creative, your funnel emails, and your influencer briefs.

Three operating realities you should plan around:

• Marketing-surface coverage is now broader than your domain. FDA’s 2025 letters cite TikTok and Instagram posts, podcast endorsements, banner ads, and quiz-funnel pages alongside service-page copy [4]. If a claim appears on a paid surface you control or sponsor, it is in scope.
• Compliance is upstream of marketing, not parallel to it. A clinic whose product page describes a compounded preparation as if it were the branded, approved drug cannot fix the problem with a disclaimer in the footer. The implied status has to come out of the headline. The same applies to equivalence claims against named brand drugs, absolute-safety language, and unsubstantiated efficacy phrasing.
• Speed of remediation is now part of the story. The 100-plus cease-and-desist letters expected near-immediate corrective action [2]. A clinic that needs three weeks to update copy is operating outside the implicit response window.

A 5-step pre-publish checklist you can run today

You do not need a compliance team to run a defensible screen on a service page or ad. Five steps, in order, cover most of the practical risk before anything goes live:

1. Search your own copy for the seven trigger categories. Language describing the product as treating or preventing a specific named disease; an implied approval status applied to a compounded preparation or dietary supplement (only specific drugs receive FDA approval for specific indications); brand-equivalence comparisons to a named drug; absolute-safety language; language asserting an absence of adverse events; outcome-promise verbs; and money-back-framed clinical promises. If any appear, treat them as flagged until reviewed.
2. Disclose compounded status in the same breath as the product name. Anywhere your copy names semaglutide, tirzepatide, or any compounded preparation, the disclosure should be present and plain. Footers do not count.
3. Pull every brand-equivalence comparison. If a sentence puts your product next to Ozempic, Wegovy, Zepbound, or Mounjaro with equivalence verbs, remove the comparison. State what your product contains; let the patient compare with the physician.
4. Audit paid social and influencer content as marketing copy. Treat any TikTok, Instagram, or podcast placement that names a drug as a regulated communication, not an organic post. Require balanced safety language and a written brief for every paid placement.
5. Run the copy through the free Claim Checker. It scans pasted text against the same FDA Warning Letter and FTC patterns we see in the Atlas, with the precedent shown next to every flag. Nothing leaves your browser, and there is no signup.

A clean checklist is a screen, not a clearance. Your clinic’s own licensed physician and your counsel are the final reviewers of any substantive medical claim. The point of screening is to spend their time on the calls that genuinely require judgment, not on phrases a tool can catch in seconds.

How Authoritize fits

Authoritize was built for exactly this risk surface. The FDA / FTC Atlas tracks the real enforcement record across all the verticals named above and is the source the Claim Checker cites back when it flags a phrase. Our content engine screens client articles against the same patterns before publication, with the clinic’s own physician signing off as the author of record. For a fast, no-cost look at your current marketing surface, the free audit returns a same-day report on the specific phrases on your site that map to the patterns covered above.

Frequently asked questions

Did the FDA actually issue more than 200 enforcement letters in 2025?

Yes. King & Spalding’s 2025 Year in Review of FDA drug and device advertising and promotion enforcement counts more than 200 letters challenging the advertising and promotion of prescription drugs across manufacturers, online retailers, telehealth providers, and compounding pharmacies, plus 32 separate Warning Letters on the medical-device side. The aggregate is the highest annual total in nearly 25 years [1].

Is my telehealth practice in scope, or is this only about pharmaceutical manufacturers?

It is in scope. More than 40 of the September 2025 warning letters went to compounding pharmacies and telehealth companies, with named recipients including Hims & Hers and eDrugstore. The FDA’s enforcement focus explicitly includes telehealth marketing surfaces and paid social media influencer posts on platforms like TikTok and Instagram [4].

Does this only matter if I sell compounded GLP-1?

No. Compounded GLP-1 marketing drew the single largest cluster of letters on September 9 [1], but the underlying claim categories (compounded-as-approved, brand-equivalence, absolute safety, outcome promises, off-label promotion) apply to every clinic vertical, including TRT, peptides, medical spa, and stem cell or regenerative offerings [7].

What is the practical risk if my copy crosses a line?

The immediate risk is a Warning Letter or Untitled Letter that publicly quotes your marketing, plus a cease-and-desist requiring near-immediate corrective action [2]. Beyond the corrective demand, FTC action can carry monetary penalties, and the published letter becomes a permanent record competitors and patients can find. The audit-trail risk is often larger than the legal risk.

Where do I look to see the actual letters?

The FDA publishes its Warning Letters database, and the Authoritize FDA / FTC Atlas tracks the actions most relevant to clinic marketing by vertical, with the cited phrasing pulled out.

Citations

1. Cooper, S., Pao, A., et al. 2025 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement. King & Spalding. 2026. kslaw.com/news-and-insights/2025-year-in-review-fda-drug-and-device-advertising-and-promotion-enforcement. Accessed June 17, 2026.
2. U.S. Food and Drug Administration. FDA Launches Crackdown on Deceptive Drug Advertising. Press announcement. September 9, 2025. fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising. Accessed June 17, 2026.
3. Crowell & Moring LLP. FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising. September 2025. crowell.com/en/insights/client-alerts/fda-announces-intention-to-initiate-an-aggressive-enforcement-campaign-against-misleading-pharmaceutical-advertising. Accessed June 17, 2026.
4. Levy, T. FDA’s Deceptive Drug Ad Focus Leaves Telehealth Sites Guessing. Bloomberg Government. September 2025. news.bgov.com/health-law-and-business/fdas-deceptive-drug-ad-focus-leaves-telehealth-sites-guessing. Accessed June 17, 2026.
5. Pro-Pharma Group. FDA’s Crackdown on Drug Advertising: Key Lessons from 60 Compliance Letters in 2025. propharmagroup.com/thought-leadership/fda-crackdown-drug-advertising-key-lessons-2025-compliance-letters. Accessed June 17, 2026.
6. Latham & Watkins. FDA Begins Crackdown on Direct-to-Consumer Pharmaceutical Advertising. September 2025. lw.com/en/insights/fda-begins-crackdown-on-direct-to-consumer-pharmaceutical-advertising. Accessed June 17, 2026.
7. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. Accessed June 17, 2026.
8. Federal Trade Commission. Health Products Compliance Guidance. December 2022. ftc.gov/business-guidance/resources/health-products-compliance-guidance. Accessed June 17, 2026.
9. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act. Accessed June 17, 2026.